Vickie S. Reed

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
La Jolla, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Matthew J. D'Onofrio, Attorney-in-fact for Vickie S. Reed
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Vickie S. Reed

Form 4 holding SVP, Chief Accounting Officer

Mirati Therapeutics, Inc.

Security class
Common Stock
Shares / value
15,369
Estimated value
$907,078
Report date
18 Jan 2022
Price
$59.02
Ownership
Direct
Form 4 holding Director

Adamis Pharmaceuticals Corp

Security class
Stock Appreciation Right
Shares / value
50,000
Estimated value
Report date
24 May 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding SVP, Chief Accounting Officer

Mirati Therapeutics, Inc.

Security class
Employee Stock Option (Right to Buy)
Shares / value
8,910
Estimated value
Report date
14 Jan 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Evoke Pharma Inc

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
17 Dec 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Vickie S. Reed

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .